79 related articles for article (PubMed ID: 23569125)
1. Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel therapeutic target for diabetic complications.
Xu X; Luo P; Wang Y; Cui Y; Miao L
J Int Med Res; 2013 Feb; 41(1):13-9. PubMed ID: 23569125
[TBL] [Abstract][Full Text] [Related]
2. Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much?
Tan SM; de Haan JB
Redox Rep; 2014 May; 19(3):107-17. PubMed ID: 24559141
[TBL] [Abstract][Full Text] [Related]
3. Protective role of NRF2 in macrovascular complications of diabetes.
Wu J; Sun X; Jiang Z; Jiang J; Xu L; Tian A; Sun X; Meng H; Li Y; Huang W; Jia Y; Wu H
J Cell Mol Med; 2020 Aug; 24(16):8903-8917. PubMed ID: 32628815
[TBL] [Abstract][Full Text] [Related]
4. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades.
Negi G; Kumar A; Sharma SS
J Pineal Res; 2011 Mar; 50(2):124-31. PubMed ID: 21062351
[TBL] [Abstract][Full Text] [Related]
5. Current Status and Challenges of NRF2 as a Potential Therapeutic Target for Diabetic Cardiomyopathy.
Ge ZD; Lian Q; Mao X; Xia Z
Int Heart J; 2019 May; 60(3):512-520. PubMed ID: 30971629
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective.
Hashemi M; Zandieh MA; Ziaolhagh S; Mojtabavi S; Sadi FH; Koohpar ZK; Ghanbarirad M; Haghighatfard A; Behroozaghdam M; Khorrami R; Nabavi N; Ren J; Reiter RJ; Salimimoghadam S; Rashidi M; Hushmandi K; Taheriazam A; Entezari M
Biochim Biophys Acta Mol Basis Dis; 2023 Jun; 1869(5):166714. PubMed ID: 37028606
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle.
Negi G; Kumar A; Joshi RP; Sharma SS
Biochem Biophys Res Commun; 2011 Apr; 408(1):1-5. PubMed ID: 21439933
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 as molecular target for polyphenols: A novel therapeutic strategy in diabetic retinopathy.
Nabavi SF; Barber AJ; Spagnuolo C; Russo GL; Daglia M; Nabavi SM; Sobarzo-Sánchez E
Crit Rev Clin Lab Sci; 2016 Oct; 53(5):293-312. PubMed ID: 26926494
[TBL] [Abstract][Full Text] [Related]
9. Long-term diabetic complications may be ameliorated by targeting Rho kinase.
Zhou H; Li Y
Diabetes Metab Res Rev; 2011 May; 27(4):318-30. PubMed ID: 21309060
[TBL] [Abstract][Full Text] [Related]
10. Complement activation and diabetic vascular complications.
Østergaard J; Hansen TK; Thiel S; Flyvbjerg A
Clin Chim Acta; 2005 Nov; 361(1-2):10-9. PubMed ID: 15996650
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis.
Yi M; Toribio AJ; Salem YM; Alexander M; Ferrey A; Swentek L; Tantisattamo E; Ichii H
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892018
[TBL] [Abstract][Full Text] [Related]
12. Role of oxidative stress in diabetic bone disorder.
Hamada Y; Fujii H; Fukagawa M
Bone; 2009 Jul; 45 Suppl 1():S35-8. PubMed ID: 19232402
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation.
Hybertson BM; Gao B; Bose SK; McCord JM
Mol Aspects Med; 2011 Aug; 32(4-6):234-46. PubMed ID: 22020111
[TBL] [Abstract][Full Text] [Related]
14. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development.
Marhenke S; Lamlé J; Buitrago-Molina LE; Cañón JM; Geffers R; Finegold M; Sporn M; Yamamoto M; Manns MP; Grompe M; Vogel A
Hepatology; 2008 Aug; 48(2):487-96. PubMed ID: 18666252
[TBL] [Abstract][Full Text] [Related]
15. [Nrf2 as a chemoprevention target in gastrointestinal carcinoma].
Gao P; Tang XW; Wang XJ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Jul; 41(4):453-63. PubMed ID: 22927084
[TBL] [Abstract][Full Text] [Related]
16. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway.
Scannevin RH; Chollate S; Jung MY; Shackett M; Patel H; Bista P; Zeng W; Ryan S; Yamamoto M; Lukashev M; Rhodes KJ
J Pharmacol Exp Ther; 2012 Apr; 341(1):274-84. PubMed ID: 22267202
[TBL] [Abstract][Full Text] [Related]
17. Curcumin induces a nuclear factor-erythroid 2-related factor 2-driven response against oxidative and nitrative stress after praziquantel treatment in liver fluke-infected hamsters.
Charoensuk L; Pinlaor P; Prakobwong S; Hiraku Y; Laothong U; Ruangjirachuporn W; Yongvanit P; Pinlaor S
Int J Parasitol; 2011 May; 41(6):615-26. PubMed ID: 21256849
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes.
He X; Kan H; Cai L; Ma Q
J Mol Cell Cardiol; 2009 Jan; 46(1):47-58. PubMed ID: 19007787
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of Nrf-2 pathway in the treatment of diabetic neuropathy and nephropathy.
Gupta A; Behl T; Sehgal A; Bhatia S; Jaglan D; Bungau S
Mol Biol Rep; 2021 Mar; 48(3):2761-2774. PubMed ID: 33754251
[TBL] [Abstract][Full Text] [Related]
20. [Type-2 diabetes mellitus as a cause of disability].
Piechota G; Małkiewicz J; Karwat ID
Przegl Epidemiol; 2004; 58(4):677-82. PubMed ID: 15810510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
